MGX Earnings

Quarterly EPS
$-0.51
Q3 2024
$-0.62
Q4 2024
$-0.68
Q1 2025
$-0.54
Q2 2025
$-0.55
Q3 2025
$-0.60
Q4 2025
$-0.61
Q1 2026
$-0.73
Q2 2026
Latest Revenue-257000
Latest Net Income-27482000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.73-257000-27482000-103.0%-35.2%
Q1 2026-$0.611.2M-23059000-69.8%+10.3%
Q4 2025-$0.603.9M-22528000-59.3%+3.2%
Q3 2025-$0.558.7M-20393000-24.8%-7.8%
Q2 2025-$0.548.5M-19908000-57.5%-86.2%
Q1 2025-$0.684.1M-25039000-63.0%+42.9%
Q4 2024-$0.629.6M-23398000
Q3 2024-$0.5111.5M-18773000
Q2 2024-$0.2920.0M-10739000
Q1 2024-$1.1911.2M-25148000
Metagenomi Therapeutics (MGX) — Earnings